Associated Papers
The hidden burden of kidney damage in chylomicronemia syndromes.
D'Erasmo L et al.
Atherosclerosis, 2026
Contemporary Management of Familial and Multifactorial Chylomicronemia Syndromes in Italy: Insights From the National LIPIGEN Registry.
D'Erasmo L et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2025
41099101 (PubMed )
Supplement: atv-45-2264-s001.pdf
Pancreatitis as a Main Consequence of APOC2-Related Hypertriglyceridemia: The Role of Nonsense and Frameshift Variants.
Rabbani B et al.
International Journal of Genomics, 2024
The clinical and laboratory investigation of dysbetalipoproteinemia.
Boot CS et al.
Critical Reviews in Clinical Laboratory Sciences, 2020
Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias.
Dron JS et al.
Bmc Medical Genomics, 2020
32041611 (PubMed )
Supplement: 12920_2020_669_MOESM1_ESM.xlsx › Supp_Table_4
Spectrum of Mutations and Long-Term Clinical Outcomes in Genetic Chylomicronemia Syndromes.
D'Erasmo L et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2019
Severe Combined Dyslipidemia With a Complex Genetic Basis.
Le R et al.
Journal of Investigative Medicine High Impact Case Reports, 0
Select a paper to view details